blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2453876

EP2453876 - HDL COMPRISING A THERAPEUTIC AGENT AND USE IN THERAPY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.06.2018
Database last updated on 05.10.2024
FormerExamination is in progress
Status updated on  26.02.2018
Most recent event   Tooltip01.06.2018Application deemed to be withdrawnpublished on 04.07.2018  [2018/27]
Applicant(s)For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris / FR
[2012/21]
Inventor(s)01 / MEILHAC, Olivier
U698 INSERM - GH BICHAT - CLAUDE BERNARD
46 rue Henri Huchard
Bâtiment INSERM 13
F-75877 Paris Cedex 18 / FR
 [2012/21]
Representative(s)Plasseraud IP
104 Rue de Richelieu
CS92104
75080 Paris Cedex 02 / FR
[N/P]
Former [2012/21]Cabinet Plasseraud
52, rue de la Victoire
75440 Paris Cedex 09 / FR
Application number, filing date10734980.516.07.2010
WO2010EP60330
Priority number, dateEP2009030567816.07.2009         Original published format: EP 09305678
[2012/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011006994
Date:20.01.2011
Language:EN
[2011/03]
Type: A1 Application with search report 
No.:EP2453876
Date:23.05.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 20.01.2011 takes the place of the publication of the European patent application.
[2012/21]
Search report(s)International search report - published on:EP20.01.2011
ClassificationIPC:A61K9/127, A61K38/17
[2012/21]
CPC:
A61K38/57 (EP,US); A61K9/1275 (EP,US); A61P11/00 (EP);
A61P17/00 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P35/00 (EP); A61P39/00 (EP); A61P43/00 (EP);
A61P7/02 (EP); A61P7/04 (EP); A61P9/10 (EP);
G01N2800/2871 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/21]
TitleGerman:HDL MIT EINEM THERAPEUTIKUM UND VERWENDUNG FÜR EINE THERAPIE[2012/21]
English:HDL COMPRISING A THERAPEUTIC AGENT AND USE IN THERAPY[2012/21]
French:HDL COMPRENANT UN AGENT THÉRAPEUTIQUE ET UTILISATION EN THÉRAPIE[2012/21]
Entry into regional phase16.01.2012National basic fee paid 
16.01.2012Designation fee(s) paid 
16.01.2012Examination fee paid 
Examination procedure16.01.2012Amendment by applicant (claims and/or description)
16.01.2012Examination requested  [2012/21]
17.05.2013Despatch of a communication from the examining division (Time limit: M04)
11.09.2013Reply to a communication from the examining division
13.06.2016Despatch of a communication from the examining division (Time limit: M04)
30.08.2016Reply to a communication from the examining division
01.02.2018Application deemed to be withdrawn, date of legal effect  [2018/27]
27.02.2018Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2018/27]
Divisional application(s)EP13185152.9  / EP2676659
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.05.2013
Fees paidRenewal fee
23.07.2012Renewal fee patent year 03
24.07.2013Renewal fee patent year 04
23.07.2014Renewal fee patent year 05
24.07.2015Renewal fee patent year 06
22.07.2016Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.07.201708   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO03018047  (ZLB BIOPLASMA AG [CH], et al) [X] 1-5 * page 1, par.1; page 2, par.3; page 3, last par.; page 4, par.3; page 5, par.2-4; page 6, par.3; examples; *;
 [IY]WO2006100567  (CERENIS THERAPEUTICS S A [FR], et al) [I] 1-5 * paragraphs [0040] - [0042] - [0058] , [0059] , [0066] - [0071] - [0107] , [0111] , [0112] , [0123] - [0125] - [0130] , [0139] - [0145] * [Y] 1-5;
 [XY]US2009110739  (LACKO ANDRAS G [US], et al) [X] 1-5 * paragraphs [0047] - [0064] - [0066] - [0068] - [0088] , [0106]; figures 1-17; example 3 * [Y] 1-5;
 [A]WO2009025754  (CSL BEHRING GMBH [DE], et al) [A] 1-5 * the whole document *
 [LD]  - VAISAR TOMAS ET AL, "Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL", JOURNAL OF CLINICAL INVESTIGATION, (200703), vol. 117, no. 3, ISSN 0021-9738, pages 746 - 756, XP007911950 [LD] 1-5 * figure 1; tables 1,2,3-5 *

DOI:   http://dx.doi.org/10.1172/JC126206
 [XY]  - ORTIZ-MUNOZ G ET AL, "ALPHA 1-ANTITRYPSIN ASSOCIATED WITH HDL INHIBITS ANOIKIS OF VASCULAR CELLS: A NEW ANTI-ATHEROGENIC PROPERTY FOR HDL", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER LNKD- DOI:10.1016/S1567-5688(08)70006-0, vol. 9, no. 1, ISSN 1567-5688, (20080501), page 2, (20080501), XP022651508 [X] 1-5 * abstract * [Y] 1-5

DOI:   http://dx.doi.org/10.1016/S1567-5688(08)70006-0
 [Y]  - ABBOUD ET AL, "Alpha1-antitrypsin deficiency", RESPIRATORY MEDICINE. COPD UPDATE, ELSEVIER, OXFORD, GB, vol. 1, no. 3, ISSN 1745-0454, (20060301), pages 80 - 87, (20060301), XP024989323 [Y] 1-5 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.rmedu.2006.01.027
 [Y]  - KOUDINOV A R ET AL, "HDL PHOSPHOLIPID: A NATURAL INHIBITOR OF ALZHEIMER'S AMYLOID BETA-FIBRILLOGENESIS?", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, WALTER DE GRUYTER & CO, BERLIN, NEW YORK, (19991001), vol. 37, no. 9, ISSN 1434-6621, page 993/994, XP000996279 [Y] 1-5 * the whole document *

DOI:   http://dx.doi.org/10.1515/CCLM.1999.148
 [YD]  - RENSEN P C N ET AL, "Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting", ADVANCED DRUG DELIVERY REVIEWS 20010425 ELSEVIER NL, (20010425), vol. 47, no. 2-3, doi:DOI:10.1016/S0169-409X(01)00109-0, pages 251 - 276, XP002273271 [YD] 1-5 * abstract * * point 5: page 265-269 *

DOI:   http://dx.doi.org/10.1016/S0169-409X(01)00109-0
 [Y]  - SCHNEEBERGER S ET AL, "Protease inhibitors as a potential target in modulation of postischemic inflammation", DRUG NEWS AND PERSPECTIVES, PROUS SCIENCE LNKD- DOI:10.1358/DNP.2002.15.9.840061, (20020101), vol. 15, no. 9, ISSN 0214-0934, pages 568 - 574, XP009021572 [Y] 1-5 * abstract * * page 571, column l, paragraph last - page 571, column middle, paragraph 1 *

DOI:   http://dx.doi.org/10.1358/dnp.2002.15.9.840061
 [Y]  - DE CASTRO RIBEIRO M ET AL, "Thrombin in ischemic neuronal death", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US LNKD- DOI:10.1016/J.EXPNEUROL.2005.11.017, vol. 198, no. 1, ISSN 0014-4886, (20060301), pages 199 - 203, (20060301), XP024945742 [Y] 1-5 * figure 2b *

DOI:   http://dx.doi.org/10.1016/j.expneurol.2005.11.017
 [Y]  - KATO NOBUYOSHI ET AL, "Effects of trans-4-aminomethylcyclohexane carboxylic acid as an antifibrinolytic agent on arterial wall and experimental atherosclerotic lesions in rabbits", THROMBOSIS ET DIATHESIS HAEMORRHAGICA, SCHATTAUER, DE, (19700101), vol. 24, no. 1, ISSN 0563-4954, pages 85 - 89, XP009139202 [Y] 1-5 * abstract * * Discussion *
by applicantEP1425031
 US5652339
    - BG CHOI ET AL., "The role of high-density lipoprotein cholesterol in atherothrombosis", MT SINAI J MED., (200607), vol. 73, no. 4, pages 690 - 701
    - RC HUBBARD ET AL., "Alpha-1 antitrypsin augmentation therapy for alpha-1 antitrypsin deficiency", AM J MED., (19880624), vol. 84, no. 6A, pages 52 - 62
    - KARLSSON H ET AL., "Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry", PROTEOMICS, (2005), vol. 5, no. 5, pages 1431 - 45
    - T VAISAR ET AL., "Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL", J CLIN INVEST., (2007), vol. 117, no. 3, pages 746 - 56
    - PC RENSEN ET AL., "Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting", ADV DRUG DELIV REV., (20010425), vol. 47, no. 2-3, pages 251 - 76
    - RG NOGUEIRA ET AL., "Endovascular approaches to acute stroke, part 2: a comprehensive review of studies and trials", AJNR AM J NEURORADIOL., (200905), vol. 30, no. 5, pages 859 - 75
    - M MAZIGHI ET AL., "Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study", LANCET NEUROL, (200909), vol. 8, no. 9, pages 802 - 9
    - PROC. NATL. ACAD. SCI., (1995), vol. 92, pages 2313 - 2317
    - LI W ET AL., "Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha-1 antitrypsin serpin", CANCER RES., (20041201), vol. 64, no. 23, pages 8657 - 65
    - UETSUJI S ET AL., "Effect of aprotinin on metastasis of Lewis lung tumor in mice", SURG TODAY, (1992), vol. 22, no. 5, pages 439 - 42
    - AM HOUGHTON ET AL., "Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth", NAT MED., (201002), vol. 16, no. 2, pages 219 - 23
    - ANDRADE-GORDON P ET AL., "Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats", J PHARMACOL EXP THER., (200107), vol. 298, no. 1, pages 34 - 42
    - Z S NEDELJKOVIC ET AL., "Mechanisms of oxidative stress and vascular dysfunction", POSTGRADUATE MEDICAL JOURNAL, (2003), vol. 79, pages 195 - 200
    - N. DHALLA; A ELMOSELHI; T HATA; N MAKINO, "Status of myocardial antioxidants in ischemiareperfusion injury", CARDIOVASCULAR RESEARCH, (2000), vol. 47, no. 3, pages 446 - 456
    - A CANTIN ET AL., "Oxidants, antioxidants and the pathogenesis of emphysema", EUR J RESPIR DIS SUPPL., (1985), vol. 139, pages 7 - 17
    - B MOOSMANN ET AL., "Antioxidants as treatment for neurodegenerative disorders", EXPERT OPINION ON INVESTIGATIONAL DRUGS, (200210), vol. 11, no. 10, pages 1407 - 1435
    - JE SCHNEIDER ET AL., "Probucol decreases neointimal formation in a swine model of coronary artery balloon injury: A possible role for antioxidants in restenosis", CIRCULATION, vol. 88, pages 628 - 637
    - S MARX ET AL., "The Development of Rapamycin and Its Application to Stent Restenosis", CIRCULATION, (2001), vol. 104, page 852
    - R.T. CALADO ET AL., "HFE gene mutations in coronary atherothrombotic disease", BRAZ J MED BIOL RES., (200003), vol. 33, no. 3, pages 301 - 6
    - C ALTAMURA ET AL., "CeruloplasminlTransferrin system is related to clinical status in acute stroke", STROKE, (20090219), vol. 40, no. 4, pages 1282 - 8
    - D GERLACH ET AL., ALTERED BRAIN METABOLISM OF IRON AS A CAUSE OF NEURODEGENERATIVE DISEASES?, vol. 63, no. 3, pages 793 - 807
    - MORALES A; FERNANDEZ-CHECA JC, "Pharmacological modulation of sphingolipids and role in disease and cancer cell biology", MINI REV MED CHEM., (2007), vol. 7, no. 4, pages 371 - 82
    - BELAYEV L ET AL., "Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia", STROKE, (2009), vol. 40, no. 9, pages 3121 - 6
    - KEYES KT ET AL., "Resolvin E1 protects the rat heart against reperfusion injury", AM J PHYSIOL HEART CIRC PHYSIOL., (2010), vol. 299, no. 1, pages H153 - 64
    - DJEU JY; WEI S., "Clusterin and chemoresistance", ADV CANCER RES., (2009), vol. 105, pages 77 - 92
    - RODRIGUEZ ET AL., "Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin", THROMB HAEMOST., (200904), vol. 101, no. 4, pages 665 - 73
    - BB WEKSLER ET AL., "Blood-brain barrier-specific properties of a human adult brain endothelial cell line", FASEB J., (200511), vol. 19, no. 13, pages 1872 - 4
    - W LIU W ET AL., "Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia", STROKE, (200907), vol. 40, no. 7, pages 2526 - 31
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.